Metagenomi Therapeutics (MGX) Equity Ratio (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Equity Ratio data on file, last reported at 0.7 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.7, down 2.01% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.7 (down 2.01% YoY), and the FY2025 annual result was 0.72, down 0.86% from the prior year.
• Equity Ratio eased to 0.7 in Q1 2026 per MGX's latest filing, from 0.72 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.72 in Q4 2024 and troughed at 0.37 in Q4 2023.
• A 4-year average of 0.6 and a median of 0.71 in 2025 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2024 and 2026: Equity Ratio soared 294.69% in 2024, then dropped 2.01% in 2026.
• A 4-year view of Equity Ratio shows it stood at 0.37 in 2023, then soared by 294.69% to 0.72 in 2024, then declined by 0.86% to 0.72 in 2025, then retreated by 2.47% to 0.7 in 2026.
• Business Quant data shows MGX's Equity Ratio at 0.7 in Q1 2026, 0.72 in Q4 2025, and 0.72 in Q3 2025.